Using MRI to Predict Rectal Cancer Response After Chemoradiation
Part of Cancer, Digestive system clinical trials.
This study uses MRI scans to predict whether rectal cancer has gone away completely after chemoradiation. It could help patients and doctors decide on the next treatment step, such as surgery or a watch-and-wait approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a confirmed diagnosis of locally advanced rectal cancer.
- You have either already completed or are about to start chemoradiation therapy.
- Your planned treatment after chemoradiation is either surgery or a watch-and-wait approach.
- You must be covered by the French Social Security System.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special type of MRI scan (called amide proton transfer-weighted imaging) to look at your rectal cancer before and after chemotherapy and/or radiation. The goal is to see if the scan can predict whether the cancer has completely disappeared by the time of surgery, which could help guide future treatment decisions.
This study looks at how an MRI “score” (mrTRG) matches how well locally advanced rectal cancer shrinks after pre-surgery chemotherapy and radiation. The goal is to use MRI results to better predict treatment response and guide care.
This study looks at whether a special scan called PET-MRI can better show how rectal cancer responds to treatment given before surgery. If it works well, it could help doctors plan the right next steps after chemoradiotherapy.
This study is testing a special PET/MRI scan to see if it can better guide treatment for stage 2 or 3 rectal cancer. You may qualify if you have locally advanced rectal cancer and are planning to get chemo and radiation before surgery.
This study uses special MRI scans taken before and during immunotherapy to see if the cancer is truly growing or just appearing to grow, which is called 'pseudoprogression'. It helps doctors better understand how well the treatment is working for rectal cancer.
This study uses an AI computer program to read special MRI images and predict how well treatment (given before surgery) will work for people with locally advanced rectal cancer. It may help doctors better plan who benefits most from neoadjuvant therapy (treatment before surgery).
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.